Phase I clinical study of the drug candidate IRL757 in healthy adults aged 65 and older
Latest Information Update: 17 Oct 2024
At a glance
- Drugs IRL-757 (Primary)
- Indications Neurodegenerative disorders
- Focus Adverse reactions
- 17 Oct 2024 New trial record
- 08 Oct 2024 According to an IRLAB Therapeutics media release,the study is expected to be completed in the end of Q4 2024.
- 08 Oct 2024 According to an IRLAB Therapeutics media release, dosing has been initiated in a Phase I clinical study of the drug candidate IRL757 in healthy adults aged 65 and older. The received milestone payment of USD 2.5 million.